Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study
机构：[1]Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]The First Hospital of Hebei Medical University, Shijiazhuang, China[3]The Affiliated Hospital of Qingdao University, Qingdao, China[4]HanDan Central Hospital, Handan, China[5]Dongfang Hospital Beijing University of Chinese Medicine, Beijing, China[6]Qingdao Central Hospital, Qingdao Central Medical Group, Qingdao, China[7]Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University, Beijing, China[8]State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China[9]The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China[10]Xuanwu Hospital Capital Medical University, Beijing, China首都医科大学宣武医院[11]The First Hospital of Jilin University, Changchun, China[12]The Second Affiliated Hospital of Harbin Medical University, Harbin, China[13]Chui Yang Liu Hospital affiliated to Tsinghua University, Beijing, China
Aims: To compare cyclosporine (CSA) combining eltrombopag (EPAG) with or without antithymocyte globulin (ATG) in aplastic anemia (AA) patients in the real world.Methods: AA patients who received ATG combining CSA and EPAG (Group A) and CSA + EPAG (Group B) as front-line treatment in 13 medical centers in China were enrolled. The efficacy and safety were compared.Results: A total of 89 patients were enrolled with 51 patients in Group A and 38 patients in Group B. The 6-month overall response (OR)/complete response (CR) was 73.3%/24.4% and 60.6%/27.3% in Groups A and B (p > .1). For severe AA patients, the 6-month OR was 74.1% versus 50% and 6-month CR was 25.9% versus 20% in Groups A and B (p > 0.1). Multivariate analysis showed gender affects the 6-month OR with females better OR (p = .017, OR 6.045, 95% CI: 1.377-26.546) and time from disease onset to treatment affected the 12-month CR (p = .026, OR 0.263, 95% CI: 0.081-0.852). No difference was found in side effects except ATG infusion reaction and serum sickness. Mortality was 7.8% in Group A and no patient died in Group B.Conclusions: CSA + EPAG had a similar response and less side effects compared with standard immunosuppressive therapy + EPAG in newly diagnosed AA.
基金：
National Natural Science Foundation of China (NSFC) [81970106]; CAMS Innovation Fund for Medical Sciences [CIFMS 2021-I2M-1-003]; National High Level Hospital Clinical Research Funding [2022-PUMCH-C-026, 2022-PUMCH-B-048]
第一作者机构：[1]Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
通讯作者：
通讯机构：[1]Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[*1]Department of Hematology, Peking Union Medical College Hospital, No. 1 ShuaiFuYuan, Dongcheng District, Beijing 100730, China
推荐引用方式(GB/T 7714)：
Chen Miao,Liu Qingchi,Gao Yan,et al.Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study[J].EUROPEAN JOURNAL OF HAEMATOLOGY.2023,111(3):407-413.doi:10.1111/ejh.14021.
APA：
Chen, Miao,Liu, Qingchi,Gao, Yan,Suo, Xiaohui,Ding, Xiaoqing...&Han, Bing.(2023).Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study.EUROPEAN JOURNAL OF HAEMATOLOGY,111,(3)
MLA：
Chen, Miao,et al."Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study".EUROPEAN JOURNAL OF HAEMATOLOGY 111..3(2023):407-413
